[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier Annecy Genevois\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":197},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,76,100,133,156,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100642193","restrictions-on-maternity-ward-visits-current-situation-challenges-and-recommendations-in-the-auvergne-rhone-alpes-region-aura-100642193",false,"NCT07653646","Restrictions on Maternity Ward Visits: Current Situation, Challenges and Recommendations in the Auvergne Rhone-Alpes Region (AuRA)","Restrictions on Maternity Ward Visits: Current Situation, Challenges and Recommendations in the AuRA Region","VISIMAT","Inclusion Criteria:\n\n* Adult female patient (aged 18 or over),\n* Female patient admitted to the maternity ward with her newborn baby or babies,\n* Length of stay in the maternity ward of 48 hours or more,\n* Female patient who has been informed about the study and has given her free, informed verbal consent to participate in the study.\n\nExclusion Criteria:\n\n* Patients who have already participated in this study,\n* Patients whose newborn(s) are hospitalised in neonatal units, neonatal intensive care units or neonatal resuscitation units,\n* Patients who have given birth to three or more newborns (triplets or more),\n* Patient whose newborn(s) has\u002Fhave died,\n* Patient unable to understand spoken or written French, making self-assessment impossible,\n* Patient under guardianship, curatorship or placed under judicial protection,\n* Patient not covered by the French social security system.","FEMALE","18 Years",{"count":20,"type":21},8000,"ESTIMATED","INTERVENTIONAL",[24],"NA","Maternal mental health in the postpartum period is a major public health issue in France. The 2021 National Perinatal Survey highlights high prevalence rates of mental health disorders among mothers, with 27.6% experiencing anxiety disorders, 16.7% experiencing depressive disorders and 5.4% having suicidal thoughts. Between 2016 and 2018, suicide was also the leading cause of maternal mortality in the year following childbirth, underscoring the severity and frequency of these disorders. In response, international guidelines, notably those of the World health Organisation (WHO), as well as national policies such as the 'First 1,000 Days' strategy, emphasise the importance of early, enhanced and individualised postnatal support. In France, this postpartum care tends to be structured around the Early Postnatal Interview and the recommended use of validated screening tools such as the Edinburgh Postnatal Depression Scale (EPDS).\n\nHowever, the quality of postpartum care depends not only on screening and clinical follow-up, but also on organisational and environmental factors. Among these, the arrangements for maternity ward visits constitute a potential determinant of patients' experiences, likely to influence both their mental state, their rest, the establishment of breastfeeding and, indirectly, the health of the newborn. The exceptional measures implemented during the Covid-19 pandemic, notably the restriction of visits, have shown generally favourable effects, with improved satisfaction among patients and healthcare staff, better conditions for rest, facilitation of breastfeeding and a perceived improvement in working conditions.\n\nHowever, these data were collected in an exceptional health context, which may introduce biases linked to the social, emotional and organisational constraints specific to this period. Their extrapolation to routine practice therefore remains uncertain. Furthermore, in the absence of specific national guidelines governing maternity ward visits, the current regulatory framework remains unclear and practices vary between institutions, often relying on local decisions that have not been scientifically evaluated.\n\nAgainst this backdrop, the VISIMAT study aims to characterise maternity ward visiting arrangements outside of any exceptional circumstances and to assess their impact on the health of mothers and newborns, as well as on healthcare workers' working conditions. Its aim is to provide a scientific basis to inform the development of standardised recommendations and prevention messages.",[27,28],"Post Partum Women","Newborn Health",[30,31,32],"maternity wards visiting","mother health","newborn health","NOT_YET_RECRUITING","2026-06-16",{"date":36,"type":37},"2026-06-17","ACTUAL",{"date":39,"type":21},"2026-06-15",{"date":41,"type":21},"2028-06",{"name":43,"class":44},"Centre Hospitalier Annecy Genevois","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100642137","role-of-viscoelastometric-testing-in-the-development-and-validation-of-a-clinical-biological-score-for-predicting-bleeding-in-patients-with-malignant-haematological-disorders-and-severe-thrombocytopenia-100642137","NCT07653672","Role of Viscoelastometric Testing in the Development and Validation of a Clinical-biological Score for Predicting Bleeding in Patients With Malignant Haematological Disorders and Severe Thrombocytopenia","VISCOTHEM-2","Inclusion Criteria:\n\n* Adult patients;\n* Who have been informed about the study and have freely given their informed consent to participate in the study;\n* With a malignant haematological disorder or bone marrow failure, whether treated or untreated and at any stage of treatment;\n* With central thrombocytopenia strictly below 20 G\u002FL in a blood sample taken less than 72 hours ago and not having received a transfusion since;\n* Admitted to a haematology day unit or inpatient ward, or being followed up at a haematology outpatient clinic;\n* With or without active bleeding;\n* Affiliated with or covered by a social security scheme.\n\nExclusion Criteria:\n\n* Patients who have received at least one of the following treatments:\n* Antiplatelet agents within 7 days prior to enrolment,\n* Vitamin K antagonists within 7 days prior to enrolment,\n* Direct oral anticoagulants within 72 hours prior to enrolment,\n* Low molecular weight heparin within 24 hours prior to inclusion,\n* Unfractionated heparin within 6 hours prior to inclusion,\n* Bruton's tyrosine kinase inhibitor (ibrutinib, zanubrutinib or acalabrutinib) within 72 hours prior to inclusion;\n* Patients with a history of thrombopathy;\n* Patients with a history of haemostatic disorders carrying a risk of haemorrhage or thrombosis;\n* Thrombocytopenia associated with immune thrombocytopenic purpura or disseminated intravascular coagulation;\n* Patients already enrolled in the study;\n* Pregnant or breastfeeding women;\n* Patients under guardianship or curatorship;\n* Patients who do not understand French;\n* Patients under judicial protection.","ALL",{"count":55,"type":21},410,"5 Days","OBSERVATIONAL","The goal of this single-center, non-controlled, non-randomized exploratory clinical trial is To develop and validate a clinical-biological score (VISCOTHEM score) incorporating viscoelastometric tests parameters; based on an association study, and to establish a threshold that enables the prediction of the immediate risk of bleeding in haematology patients with severe thrombocytopenia (\\\u003C20 G\u002FL); with a view to selecting a population with a residual risk of bleeding of zero (NPV ≥ 95%, to achieve a residual probability of bleeding \\\u003C 5%).\n\nThe score may incorporate variables identified in the literature as having a plausible causal relationship with the occurrence of bleeding (14,15), as well as viscoelastometric tests parameters, conventional haemostasis parameters and relevant clinical parameters. .\n\nParticipants will undergo an additional blood sample to standard care. The total volume of blood drawn will be 21.1 mL. The following analyses will be performed: Quantra®, Rotem®, blood count, platelets, immature platelet count, plasma prothrombin time, activated partial thromboplastin time, International Normalized Ratio, fibrinogen, urea, creatinin, albumin.",[60,61,62,63],"Thrombocytopenia","Platelet Transfusion","Haemorrhage","Hematologic Malignancies",[65,66,67,68,69],"viscoelasticity test","thrombocytopenia","haematologic disease","risk of bleeding","clinical and laboratory score",{"date":36,"type":37},{"date":72,"type":21},"2026-06-30",{"date":74,"type":21},"2028-07-15",{"name":43,"class":44},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":45},"100641558","evaluation-of-depression-screening-methods-administered-by-registered-nurses-in-chronic-hemodialysis-patients-100641558","NCT07651436","Evaluation of Depression Screening Methods Administered by Registered Nurses in Chronic Hemodialysis Patients","IDE-3D","Inclusion Criteria:\n\n* Patient informed about the nature, process, and objectives of the study and having signed a free and informed consent to participate,\n* Patient treated with conventional hemodialysis for at least 3 months and currently undergoing dialysis 3 times a week,\n* Patient covered by the french national social welfare\n\nExclusion Criteria:\n\n* Patient suffering from dementia\n* Pregnant or breastfeeding patient\n* Patient unable to understand the French language both orally and in writing, - making self-assessment impossible\n* Patient currently participating in another interventional research protocol or in an exclusion period from such research\n* Patient who has already been included in this study\n* Patient under guardianship, curatorship, or placed under judicial protection.",{"count":84,"type":21},450,[24],"Hemodialysis is a vital replacement therapy for patients with end-stage chronic kidney disease, but it imposes a heavy, demanding, and prolonged management, associated with a significant deterioration in quality of life. Hemodialysis patients are exposed to numerous physical, organizational, and social constraints, including repeated and prolonged sessions at the center, dietary and fluid restrictions, chronic fatigue, and frequent comorbidities. Therefore, depressive disorders in hemodialysis patients represent a major public health issue.\n\nThe literature reports a high prevalence of depressive symptoms among hemodialysis patients, ranging from 22% to 60%, significantly higher than that observed in the general population. These disorders are associated with a significant deterioration in quality of life, increased hospitalizations, lower therapeutic adherence, an increased risk of suicide, and excess mortality. Despite these important clinical consequences, depressive disorders often remain underdiagnosed in hemodialysis.\n\nCurrent guidelines, including those from the Haute Autorité de Santé (HAS), emphasize the importance of regular quality of life assessments in patients with chronic kidney disease and recommend the use of validated questionnaires. However, they do not formalize a specific operational strategy for screening depressive disorders in routine hemodialysis practice, contributing to their under-evaluation.\n\nThe gold standard diagnosis of depressive disorders relies on a structured psychiatric interview, which is difficult to reconcile with the organizational constraints of dialysis centers. Standardized self-assessment tools, such as the Hospital Anxiety and Depression Scale (HADS), particularly its depression subscale (HADS-D), have been widely used. The HADS-D has the advantage of excluding somatic symptoms and has been validated in hemodialysis patients.\n\nHowever, self-assessment relies on the patient's ability to express their subjective experience. Thus, the self-administration of standardized questionnaires in these patients is often challenging due to their age, comorbidities, fatigue, and functional limitations, often necessitating the intervention of healthcare staff. In contrast, registered nurses (IDE) working in hemodialysis possess longitudinal clinical knowledge of patients, acquired over repeated sessions, which can serve as a relevant lever for rapid and standardized screening of depressive symptoms. To date, the diagnostic performance of structured nursing hetero-evaluation remains poorly documented.\n\nThe IDE-3D study aims to evaluate the ability of nurses to identify depressive symptoms in hemodialysis patients using structured tools, comparing the nursing hetero-evaluation of the HADS-D with the self-assessment conducted by the patient. It is part of a pragmatic approach aimed at improving the screening of depressive disorders in hemodialysis, structuring the care pathway, and enhancing the integration of mental health into the overall management of hemodialysis patients.",[88,89],"Depressive Disorders","End-stage Chronic Kidney Disease Treated With Hemodialysis",[91,92,93],"Epidemiology","Diagnostic strategies","Mental health",{"date":95,"type":37},"2026-06-18",{"date":39,"type":21},{"date":98,"type":21},"2028-10",{"name":43,"class":44},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":108,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":45},"100610832","phase-3-prevention-of-rsv-infection-in-infants-by-administering-nirsevimab-to-infants-with-or-without-maternal-rsv-vaccination-100610832","NCT07232706","Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination","Prevention of RSV Infection in Infants by Administering Nirsevimab to Infants, With or Without Maternal RSV Vaccination: a Randomised Controlled Trial in France as Part of the Pregnancy and Infant PrEparedness pLatform IN Europe - PIPELINE","PIPELINE-RSV-F","Inclusion Criteria:\n\n1. Pregnant women\n2. Provide informed consent prior to study enrolment\n3. Willing and able (in the site investigator's opinion) to comply with all study requirements\n4. More than 18 years of age\n5. Between 32 and 36 weeks of gestation\n6. Able to read and complete the eHealth questionnaire in French or English\n7. Willing to receive maternal vaccine in pregnancy, if allocated\n8. Willing for the baby to receive infant nirsevimab\n9. Willing for their data to be re-used as part of the joint analysis with PIPELINE-RSV-International trial\n10. Affiliated to social security regime or an equivalent system\n\nInclusion Criteria - Infants:\n\n1. Live-birth to mother enrolled in the study\n2. Informed consent from the mother, and the other legal representative (partner \u002F co-parent) when applicable\n\nExclusion Criteria:\n\n1. Major illness of the maternal participant or conditions of the foetus that, in the investigator's judgment, would substantially increase the risk associated with the maternal or infant participant's participation in and completion of the study\n2. Any suspected or confirmed condition in the foetus that in the opinion of the site investigator would contraindicate participation of the future newborn\u002Finfant in the study\n3. High risk of prematurity as judged by treating clinician\n4. Multiple pregnancy (i.e. twins, triplets or more)\n5. Previous participation in the PIPELINE-RSV trial\n6. Receipt of any previous RSV prevention product in this pregnancy or currently participating in another interventional RSV prevention trial\n7. Any contraindication for receipt of intramuscular injection (bleeding diathesis or a condition associated with prolonged bleeding) or of vaccine (history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine)\n8. History of Guillain Barré Syndrome (GBS)",true,{"count":110,"type":21},1000,[112],"PHASE3","RSV (which stands for Respiratory Syncytial Virus) is an infection that causes cold-like symptoms and is most common during winter months. Most people with RSV infection get better by themselves but babies and younger children can become very poorly. About 1 in 15 infants with confirmed RSV within the first 12 months of life will be hospitalised, and a very small proportion will be seriously ill and may die.\n\nCurrently there are two different prevention options that can be used to prevent RSV infection in babies. One is a vaccine given to the mother during pregnancy, and the other is a monoclonal antibody given by injection to the baby. Although both prevention options work well on their own and are safe, neither provides 100% protection to the infant. It is not known whether giving both medicines, one to the mother in pregnancy and one to the infant, would provide better protection than giving only one medicine - this is what the PIPELINE-RSV study will look at.\n\nPIPELINE-RSV-France will recruit about 1000 pregnant women in France. A parallel trial, running across Europe (PIPELINE-RSV-International) will recruit about 1500 pregnant women in UK, Switzerland, the Netherlands and Belgium. The protocols will align on key aspects and the data will be analysed together. The study will include two study groups with different prevention options used in each: (1) an injection given to the baby at the beginning of RSV season, or (2) both a vaccine given to the mother in pregnancy and an injection given to the baby at around 4 months of age. Each mother-baby pair will be randomly allocated to group by a computer. The numbers of babies in each of these groups who acquire RSV will be compared. In some countries participating to the International trial, an other study groups may be available : (3) a vaccine given to the mother in pregnancy.\n\nPregnant women and their babies will be followed until the baby reaches 12 months of age. Information will be collected about medically-important side effects either the mother or the baby had from their medicine(s) and any symptoms of RSV the baby had. Visits with the mother and baby will occur at birth and 12 months later. The mother will complete questionnaires via a Web-based platform to report any non-routine in-person visits, once in pregnancy and after the baby is born twice a month or monthly (more often in the winter), to also report baby's symptoms, to report their trial experience when the baby is 4 and 12 months' old, and to provide their views on vaccination at birth, and when the baby is 4 and 12 months' old. If the baby develops symptoms that might be RSV, their mother or another caregiver will be asked to take a sample using a swab from the baby's nose or mouth, and to send it by post for testing to find out if the baby has RSV.\n\nAs well as the main research study, there are also some substudies. A questionnaire will be given to women who consent to take part, to find out their motivations for joining the study and how they prefer to receive information about taking part in studies. A small number of women will be asked to take part in a study to look at how mothers' and babies' immune systems respond to the two different study prevention options , and to investigate different ways of collecting samples from their babies. In addition, researchers will use data from the study to see whether giving both medicines is cost-effective compared with giving just one medicine.",[115],"RSV Immunization",[117,118,119,120,121,122,123],"nirsevimab","abrysvo","rsv","respiratory infection","Respiratory Syncytial Virus","prevention","immunization","RECRUITING","2026-05-22",{"date":127,"type":37},"2026-05-27",{"date":129,"type":37},"2026-05-06",{"date":131,"type":21},"2029-05-05",{"name":43,"class":44},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":45},"100612046","effect-of-an-intervention-combining-the-use-of-standardized-information-and-sending-an-sms-advice-message-to-parents-calling-the-samu-center-15-for-uncomplicated-fever-in-children-100612046","NCT07248488","Effect of an Intervention Combining the Use of Standardized Information and Sending an SMS Advice Message to Parents Calling the SAMU Center 15 for Uncomplicated Fever in Children","Effect of an Intervention Combining the Use of Standardized Information and Sending an SMS Advice Message to Parents Calling the SAMU Center 15 for Uncomplicated Fever in Children Over 3 Months and Under 10 Years of Age : a Regional Cluster Randomized Trial","SCF","Inclusion criteria relating to the child concerned by the call to the SAMU Centre 15:\n\n* Call for a child aged between 3 months and 10 years,\n* Presenting with fever alone (SFMU\u002FGPIP definition),\n* Developing for less than 72 hours,\n* Without clinical signs,\n* And without signs of seriousness requiring emergency medical attention (as determined by SAMU Centre 15):\n\n  * Fever ≥41°C,\n  * Impaired consciousness,\n  * Convulsions,\n  * Dyspnea,\n  * Skin rash,\n  * Dehydration.\n\nInclusion criteria relating to the caller:\n\n* Caller with parental authority over the child concerned by the call,\n* Affiliated to a social security scheme or beneficiary of a similar scheme.\n\nExclusion criteria relating to children involved in calls to the SAMU Centre 15 emergency medical service:\n\n* Children who have already been the subject of a call to the SAMU Centre 15 emergency medical service in the last 15 days,\n* Children with a history of urinary tract infection,\n* Children referred by the dispatcher during the phone call to a healthcare facility for clinical evaluation (SMUR, private ambulance, fire department, parents referred to the emergency room or primary care physician).\n\nExclusion criteria relating to the caller:\n\n* Calls made from a landline or foreign number, making it impossible to send text messages,\n* Calls made by someone who cannot read or understand French.",{"count":142,"type":21},1792,[24],"During the winter of 2022\u002F23, a standardized protocol for managing fever in children aged 3 months to 10 years was implemented at Annecy Genevois Hospital for a period of one month. This protocol included advice given by the regulator and sending a text message to parents after the call. A total of 182 calls were handled in one month: 95 during a 15-day period before the intervention was rolled out and 87 during a 15-day period during the intervention (43 with unread text messages and 44 with read text messages). All parents who read the text message understood it. The rate of compliance with advice was improved by the intervention when the text message was read (p \\\u003C 0.01), in terms of increased paracetamol intake, avoidance of cold baths, undressing the child, and administering fluids. When the text message was read, the rate of calls to the 15 emergency center fell from 13% before the intervention to 2% when the text message was read (p = 0.04). A downward trend in emergency room visits was also observed, from 13% before the intervention to 5% when the text message was read and 19% when the text message was not read (p = 0.13). These encouraging data suggest that a randomized study would demonstrate the value of this approach in routine practice.\n\nEven if the effect of such protocols is moderate, the target audience is such that their impact on the use of unscheduled care and on the healthcare system could be significant, at a low implementation cost.\n\nThe use of a standardized protocol involving the sending of text messages in cases of uncomplicated fever in children makes it possible to:\n\n* standardize the advice given by call center doctors,\n* ensure the traceability of advice,\n* help parents monitor their children.\n\nThe objective of this study is to determine, in a randomized trial, whether the combined use of standardized advice for children with fever and text messages sent to parents by the emergency medical service (EMS) can:\n\ni) reduce the use of unscheduled medical care; ii) improve compliance with advice; iii) reduce the rate of callbacks to the emergency medical service; iv) improve parent satisfaction.",[146,147],"Emergency Call","Fever; Pediatric Fever Management; Parental Anxiety","2025-11-25",{"date":150,"type":37},"2025-12-02",{"date":152,"type":21},"2026-09-07",{"date":154,"type":21},"2028-03-28",{"name":43,"class":44},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":45},"100579271","simulation-of-facial-soft-tissue-in-orthognathic-surgery-100579271","NCT06822127","Simulation of Facial Soft Tissue in Orthognathic Surgery","SPOC","Inclusion Criteria:\n\n* Patient over 18 ;\n* Patients who have been informed of the study and who have freely given their informed consent to participate in the study;\n* Patient undergoing isolated mandibular or maxillary orthognathic surgery, or maxillo-mandibular surgery with or without genioplasty for any indication (occlusal disorder, sleep apnoea syndrome, functional joint disorder, etc.);\n* Patient covered by a French social security scheme\n\nExclusion Criteria:\n\n* Patient with maxillary disjunction ;\n* Patients with facial malformations;\n* Pregnant or breast-feeding patient;\n* Patient under guardianship;\n* Patients who do not understand French;\n* Patients under court protection\n* No pre- or postoperative CT scan or CT scan that cannot be used\n* Surgery, trauma, progressive infection or cosmetic injection on the face after orthognathic surgery and before the postoperative scan",{"count":164,"type":21},30,[24],"Orthognathic surgery consists of rebalancing the position of the jaws, taking into account functional criteria (tooth engagement, tooth\u002Flip ratio, breathing, etc.) and aesthetic criteria. It has become much more accurate in recent years thanks to the advent of osteosynthesis plates and the contribution of three-dimensional imaging. Three-dimensional imaging makes it possible to simulate fairly accurately the surgical procedures and bone displacements required. However, the effect of these bone displacements on the soft tissues (skin, subcutaneous tissue, muscles) does not make it possible, with today's digital tools, to simulate the final aesthetic result and in particular to anticipate the sometimes significant postoperative changes to the face. Many patients are worried about these post-operative morphological changes and would like to have a precise idea of how they will look after surgery. Being able to offer them, before surgery, a visual solution simulating the final aesthetic appearance would be essential in this respect.\n\nThe aim of the study is to validate the predictions provided by the digital face model on a series of patients scheduled for orthognathic surgery by comparing the simulation of the morphological result of the operation, provided by our algorithm (SPOC), with the actual result assessed on a scan taken 6 months after the operation.",[168],"Orthognathic Surgery","2025-11-14",{"date":171,"type":37},"2025-11-17",{"date":173,"type":37},"2025-04-28",{"date":175,"type":21},"2027-10-31",{"name":43,"class":44},{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":124,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":195,"locationsCount":196},"100502079","response-profiles-to-high-concentration-capsaicin-desensitization-in-patients-with-peripheral-neuropathic-pain-with-or-without-allodynia-a-regional-multicenter-prospective-cohort-100502079","NCT05817591","Response Profiles to High-concentration Capsaicin Desensitization in Patients with Peripheral Neuropathic Pain with or Without Allodynia: a Regional Multicenter Prospective Cohort","CAPSICAURA","Inclusion Criteria:\n\n* Patient over 18 years of age on the day of inclusion\n* Patient who has been informed and has not expressed opposition to participating in the study,\n* Patient with peripheral neuropathic pain (whatever the etiology), defined by :\n\n  * \"Neuropathic Pain 4\" score (\"DN4\" score) ≥ 4\u002F10\n  * AND pain according to the numerical scale (EN) \\> 4\u002F10,\n  * AND stable analgesic treatment for at least 1 month,\n  * AND with or without mechanical allodynia according to the Quantitative Sensory Testing (QST) : Brush test (dynamic), Von Frey test (static)\n  * AND with or without thermal allodynia to hot or cold as determined by a ROLLTEMP-II® (Rolltemp is a device designed for quick screening of temperature sensibility over large body areas).\n* Patient responding to an indication of desensitization to high concentration capsaicin concentration and not presenting any contra-indication.\n* Patient naïve of high concentration of Capsaicin on the concerned zone\n* Patient understanding French\n\nNon-inclusion Criteria:\n\n* Patient with pain related to complex regional pain syndrome (criteria not meeting the indication for capsaicin)\n* Patient with active cancer (underlying disease and treatments may modify pain perception),\n* Patient receiving or having received in the last 3 months Botulinum toxin A on the concerned area (this treatment of neuropathic pain may modulate the effect of capsaicin and disturb the demonstration of causality),\n* Patient with planned surgery within the next 12 months on the painful site (surgery may cause neuropathic damage and\u002For bias the pain assessment),\n* Patient included in an interventional research protocol,\n* Patient under guardianship or curators,\n* Patient under legal protection\n\nExclusion Criteria:\n\nNone",{"count":185,"type":21},400,"Prospective multicenter cohort to determine patient profiles (associated factors, including allodynia) with a better response to pain desensitization by capsaicin delivered in the form of a high concentration patch (8%), in a population of patients with peripheral neuropathic pain and followed up in a pain consultation in the Auvergne Rhône Alpes region.",[188],"Peripheral Neuropathic Pain","2025-02-11",{"date":191,"type":37},"2025-02-13",{"date":193,"type":37},"2023-12-14",{"date":39,"type":21},{"name":43,"class":44},10,""]